• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NovoCure Limited - Ordinary Shares (NQ:NVCR)

    11.30 +0.58 (+5.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 992,061
    Open 10.90
    Bid (Size) 11.25 (200)
    Ask (Size) 11.30 (200)
    Prev. Close 10.72
    Today's Range 10.85 - 11.38
    52wk Range 9.820 - 20.06
    Shares Outstanding 103,647,871
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Novocure to Report First Quarter 2026 Financial Results
    From Novocure
    Via Business Wire
    News headline image
    Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
    From Novocure
    Via Business Wire

    Performance

    YTD
    -13.9%
    -13.9%
    1 Month
    -8.7%
    -8.7%
    3 Month
    -20.3%
    -20.3%
    6 Month
    -14.7%
    -14.7%
    1 Year
    -31.7%
    -31.7%

    More News

    Read More
    News headline image
    Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
    From Novocure
    Via Business Wire
    News headline image
    Novocure to Participate in 2026 Leerink Global Healthcare Conference
    From Novocure
    Via Business Wire
    News headline image
    NovoCure (NVCR) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings World Trade
    Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss ↗
    Via Chartmill
    News headline image
    Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
    From Novocure
    Via Business Wire
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
    From Novocure
    Via Business Wire
    News headline image
    Soleus Adds a Significant Number of Celcuity Shares ↗
    Via The Motley Fool
    AI: The Great Disruptor or the Great Divider? ↗
    Via Chartmill
    News headline image
    NVCR Rallies On FDA Approval For Cancer Treatment Device, Analyst Still Sees 275% Potential Upside ↗
    Via Stocktwits
    Topics Government
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
    Via Finterra
    Topics Initial Public Offering Intellectual Property
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Stocks
    News headline image
    Novocure Stock Surges Nearly 30% After Hours: FDA Clears First New Pancreatic Cancer Therapy In Almost Three Decades ↗
    Via Stocktwits
    News headline image
    U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
    From Novocure
    Via Business Wire
    News headline image
    Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
    From Novocure
    Via Business Wire
    News headline image
    NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Novocure (NVCR) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Novocure
    Via Business Wire
    News headline image
    Novocure Appoints Company President Frank Leonard as Chief Executive Officer
    From Novocure
    Via Business Wire

    Frequently Asked Questions

    Is NovoCure Limited - Ordinary Shares publicly traded?
    Yes, NovoCure Limited - Ordinary Shares is publicly traded.
    What exchange does NovoCure Limited - Ordinary Shares trade on?
    NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for NovoCure Limited - Ordinary Shares?
    The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
    What is the current price of NovoCure Limited - Ordinary Shares?
    The current price of NovoCure Limited - Ordinary Shares is 11.30
    When was NovoCure Limited - Ordinary Shares last traded?
    The last trade of NovoCure Limited - Ordinary Shares was at 04/14/26 04:00 PM ET
    What is the market capitalization of NovoCure Limited - Ordinary Shares?
    The market capitalization of NovoCure Limited - Ordinary Shares is 1.17B
    How many shares of NovoCure Limited - Ordinary Shares are outstanding?
    NovoCure Limited - Ordinary Shares has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.